MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F19%3AN0000038" target="_blank" >RIV/00064190:_____/19:N0000038 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/19:10398630 RIV/00216208:11140/19:10398630 RIV/00179906:_____/19:10398630 RIV/00669806:_____/19:10398630 and 2 more
Result on the web
<a href="http://dx.doi.org/10.21873/cgp.20140" target="_blank" >http://dx.doi.org/10.21873/cgp.20140</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/cgp.20140" target="_blank" >10.21873/cgp.20140</a>
Alternative languages
Result language
angličtina
Original language name
MiR-376b-3p Is Associated With Long-term Response to Sunitinib in Metastatic Renal Cell Carcinoma Patients
Original language description
Background/Aim: Sunitinib is a tyrosine kinase inhibitor routinely used as first-line therapy in metastatic renal cell carcinoma (mRCC). Emerging evidence suggests that microRNAs (miRNAs) could be suitable biomarkers with predictive potential in mRCC. The aim of this study was to identify miRNA-based predictive biomarkers of therapy response to avoid unnecessary therapy to non-responding patients. Patients and Methods: High-throughput miRNA microarray profiling was performed on a cohort of 47 patients treated with sunitinib. Validation of candidate miRNAs was carried out on an independent cohort of 132 mRCC patients using qRT-PCR. Results: Out of 158 miRNAs (65 down-regulated, 93 up-regulated), six miRNAs were chosen for independent validation and miR-376b-3p was confirmed to be differentially expressed in tumors of patients with primary resistance versus long-term response (p<0.0002). Conclusion: A predictive miRNA associated with progression free survival in metastatic renal cell carcinoma patients treated with sunitinib was identified.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/NV15-34678A" target="_blank" >NV15-34678A: Prognostic and predictive molecular factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
CANCER GENOMICS & PROTEOMICS
ISSN
1109-6535
e-ISSN
1790-6245
Volume of the periodical
16
Issue of the periodical within the volume
5
Country of publishing house
GR - GREECE
Number of pages
7
Pages from-to
353-359
UT code for WoS article
000483944900005
EID of the result in the Scopus database
—